New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...
One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results